Advances in Prostate Imaging and Ablative Treatment of Prostate Cancer

Friday–Saturday
June 19–20, 2015
New York City

Register online: med.nyu.edu/cme/mi
Course Description
The primary goal of this conference is to provide the urologist and radiologist with a comprehensive review of advances in prostate imaging, biopsy, and focal minimally invasive ablative therapy (MIAT) of prostate cancer. The course is designed for practicing and academic urologists and radiologists who are interested in learning about and adopting targeted prostate biopsy and MIAT for managing prostate cancer. Selecting candidates for these novel treatment options will also be emphasized.

The course will be organized into sessions focusing on prostate imaging, prostate biopsy, disease risk stratification and MIAT. The information will be disseminated via lectures, case discussions and panel discussions.

The educational focus is designed to optimize selection of candidates and delivery of MIAT for prostate cancer by: identifying the ideal biopsy strategy in order to reliably assess the extent and biological aggressiveness of the disease; discussing novel tumor markers for improving risk stratification; applying the latest advances in imaging of prostate cancer in order to improve better assessment of the site and extent of clinically significant disease and enable target biopsies; and critically examining the most promising approaches for ablating prostate cancer and presenting technological pearls to maximize outcomes following minimally invasive ablative treatment of prostate cancer.

Target Audience
This course is designed for practicing and academic urologists and radiologists who are interested in learning about, and possibly adopting, both targeted biopsy and minimally invasive ablative therapies for prostate cancer.

Statement of Need
The optimal biopsy strategy for accurate risk stratification of prostate cancer remains controversial. Practicing clinicians need to understand the pros and cons of different biopsy strategies in order to gather the clinical information to optimize treatment decisions and appropriately select men for focal MIAT of prostate cancer.

In the past year, evidence has emerged supporting MRI guided targeted biopsy. A recent survey indicated that a significant proportion of US urologists plan to acquire targeted biopsy technology in 2015. Accordingly, it is important for clinicians to examine the different perspectives on data introduced in the literature regarding diagnosis.

MRI is underutilized in the work-up of men with elevated PSA and prostate cancer. Owing to advances in multiparametric MRI (mpMRI) of the prostate, this imaging modality should be considered in the selection of candidates for biopsy and for focal therapy. While level-one evidence is not available, clinicians need to rely on the experience and consensus of those experts in the field who are investigating the role of mpMRI for localizing prostate cancer. Clinicians (urologists and radiologists) must better understand the advantages of more powerful magnets as well as diffusion imaging and contrast enhancement. Additionally, clinicians need to have strategies for assessing best timing for utilizing MRI imaging post-biopsy following ablative intervention.

There is increasing interest in minimally invasive ablative therapies for prostate cancer, yet few urologists actually offer this option to men with prostate cancer. Clinicians need to understand the various ablative treatment options in order to select the most appropriate treatment strategy and source of ablative energy. It is also important that in learning about the multiple options, clinicians appreciate the reasons why the presenters select specific ablative energy sources and technique in a case-based setting. Random TRUS guided biopsy has been shown to both under and over-stage prostate cancer.

There is new evidence that MRI guided biopsy using cognitive co-registration, co-registration with US or in bore biopsy increases specificity of prostate biopsy without decreasing sensitivity for detecting clinically significant disease. Clinicians need to know the relative benefits of these approaches for improving accuracy of prostate biopsy.

Minimally invasive ablative therapies are technically demanding procedures and clinicians need to be experienced with the equipment and procedures before incorporating them into practice. Clinicians need to learn surgical pearls from experts in the field in order to avoid complications and ensure best outcomes. There are many different options for salvage treatment following failed radiation therapy. As the body of experience with salvage treatments increases, it appears that minimally invasive ablative approaches will markedly decrease morbidity without compromising care.
Educational Objectives
After participating in this activity, clinicians should be able to:

- Evaluate the merits of 12 core random biopsy vs MRI guided in bore biopsy vs 3D co-registration of MRI and TRUS techniques to optimize assessing site and risk stratification of prostate cancer
- Describe advances in prostatic mpMRI, including contrast enhancement, and diffusion weighted imaging as well as the optimal timing for performing mpMRI post-biopsy
- Describe the ablative properties of HIFU, cryotherapy, laser and VPT, differentiate between focal, hemi-ablation and subtotal gland ablation, and select the most appropriate minimally invasive ablative therapy for management of patients’ with localized prostate cancer
- Evaluate and differentiate between different approaches for using MRI to guide prostate biopsy
- Discuss factors that enhance effectiveness of minimally invasive procedures and establish and utilize treatment strategies that decrease complications
- Analyze benefits and risks of the different treatment options for salvage procedures following recurrent disease after radiation therapy

Course Director
Herbert Lepor, MD
Professor and Martin Spatz Chairman
Department of Urology
NYU School of Medicine
Director of the Urology Service at NYUHC
New York, New York

NYU School of Medicine Faculty
William C. Huang, MD
Assistant Professor Urology
Division of Oncology
Stacy Loeb, MD, MSc
Assistant Professor of Urology and Population Health
Andrew B. Rosenkrantz, MD, MPA
Associate Professor of Radiology and Urology
Samir Taneja, MD
The James M. Neissa and Janet Riha Neissa Professor of Urologic Oncology
Professor of Radiology
Director, Division of Urologic Oncology

Guest Faculty
Gerald L. Andriole, MD
Robert K. Royce Distinguished Professor of Urologic Surgery
Washington University School of Medicine
Chief, Division of Urologic Surgery
Barnes — Jewish Hospital
St. Louis, Missouri

Mark Emberton, MD, FRCS
Professor of Interventional Oncology
Director, Division of Surgery and Interventional Science
University College London
London, United Kingdom

Jurgen J. Futterer, MD, PhD
Associate Professor of Radiology
Radboud University Nijmegen Medical Centre
The Netherlands

Leonard Gomella, MD
The Bernard W. Godwin Jr. Professor of Prostate Cancer
Chairman, Department of Urology
Jefferson Medical College
Philadelphia, Pennsylvania

Peter A. Pinto, MD
Head, Prostate Cancer Section
Director, Fellowship Program
Urologic Oncology Branch
National Cancer Institute
Bethesda, Maryland

Stephen Scionti, MD
Founder and Director
Scionti Prostate Center
Sarasota Medical Centre
Sarasota, Florida

Daniel Sperling, MD
Medical Director
Sperling Prostate Center
Livingston, New Jersey
General Information

Location
NYU Langone Medical Center
550 First Avenue (31st Street)
Alumni Hall, Farkas Auditorium
New York, NY 10016

Mailing Address and Contact Information
NYU Post-Graduate Medical School
550 First Avenue
New York, NY 10016
Phone: (212) 263-5295
Fax: (212) 263-5293

Accreditation Statement
The NYU Post-Graduate Medical School is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
The NYU Post-Graduate Medical School designates this live activity for a maximum of 16 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Statement
The NYU Post-Graduate Medical School adheres to ACCME accreditation requirements and policies, including the Standards for Commercial Support regarding industry support of continuing medical education. In order to resolve any identified conflicts of interest, disclosure information is provided during the planning process to ensure resolution of any identified conflicts. Disclosure of faculty and commercial relationships, as well as the discussion of unlabeled or unapproved use of any drug, device or procedure by the faculty, will be fully noted at the meeting.

Hotel Accommodations
Rooms are in very heavy demand in New York City; we urge you to make your reservations early. You may obtain a list of hotels located near NYU Langone Medical Center by visiting our website: http://med.nyu.edu/cme/travel

Parking
For information, please visit http://med.nyu.edu/directions-parking
We cannot validate parking for registrants.

Course Fees
<table>
<thead>
<tr>
<th>Early Bird Fees</th>
<th>Regular Fees</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full Fee: $525</td>
<td>Full Fee: $595</td>
</tr>
<tr>
<td>Reduced Fee: $515*</td>
<td>Reduced Fee: $525*</td>
</tr>
</tbody>
</table>

Early Bird Fee Ends at 3/15/15 at 11:59 pm

*Reduced Fee applies to: NYU School of Medicine alumni; former residents and fellows; physicians-in-training with letter of certification from the Chief of Service; physicians employed by the Department of Veterans Affairs Medical Center; full-time active military personnel; nurse practitioners; retired physicians; and all other non-physician healthcare professionals

Visit our secure website cme.med.nyu.edu/mi to submit online registration
FRIDAY, JUNE 19

7:15 am Registration and Continental Breakfast

8:00 Management of Clinically Localized Prostate Cancer With Minimally Invasive Ablative Therapies (MIAT): Is It Ready for Prime Time? 
Herbert Lepor, MD

8:30 Prostatic MRI: State of the Art 
Andrew B. Rosenkrantz, MD, MPA

9:00 Interpreting MRI of the Prostate 
Jurgen J. Futterer, MD, PhD

9:40 MRI of the Prostate: How it Influences Management of Prostate Cancer (Screening, Biopsy, Disease Risk Stratification and Staging) 
Samir Taneja, MD

10:10 Coffee Break

10:20 60 Year Old Man With PSA 5.0 
- MRI No Suspicious Focal Abnormalities: Is TRUS Random Biopsy Mandatory? 
- MRI Highly Suspicious 10 mm PZ Focal Abnormality: Is Random Biopsy Necessary? 
Mark Emberton, MD, FRCS

10:45 MRI of the Prostate: Integration into a Prostate Cancer Practice 
Herbert Lepor, MD

11:15 Question and Answer

11:30 Moderator: Samir Taneja, MD 
Panel Discussion/Case Presentations 
Mark Emberton, MD, FRCS 
Jurgen J. Futterer, MD, PhD 
Herbert Lepor, MD 
Peter A. Pinto, MD 
Andrew B. Rosenkrantz, MD, MPA 
Daniel Sperling, MD

12:15 – 1:15 pm Lunch Program Session

12:15 Moderator: Herbert Lepor, MD 
The Science of Vascular Photodynamic Therapy (VPT) 
Gerald L. Andriole, MD

12:25 VPT, the US Experience 
Samir Taneja, MD

12:40 VPT, the International Experience 
Gerald L. Andriole, MD

1:00 Question and Answer

1:15 Optimizing Grey Scale Prostate Ultrasound 
Stephen Scionti, MD

1:45 Can Advanced Ultrasound Differentiate Benign vs Malignant Prostate? 
Leonard Gomella, MD

2:15 In-Bore MRI Guided Prostate Biopsy: Technique and Feasibility 
Jurgen J. Futterer, MD, PhD

2:45 Coffee Break

3:00 Commercially Available 3D Co-Registration Systems 
Daniel Sperling, MD

3:20 MRI: US Co-Registration Biopsy: Rationale and the NCI Experience 
Peter A. Pinto, MD

4:00 MRI: US Co-Registration Biopsy: The NYU Experience 
Samir Taneja, MD

4:30 Moderator: Herbert Lepor, MD 
Question and Answer/Panel Discussion/Case Presentations 
Jurgen J. Futterer, MD, PhD 
Leonard Gomella, MD 
Peter A. Pinto, MD 
Stephen Scionti, MD 
Daniel Sperling, MD 
Samir Taneja, MD

5:30 pm Adjourn
**SATURDAY, JUNE 20**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 am</td>
<td>Registration and Continental Breakfast</td>
<td></td>
</tr>
<tr>
<td>8:00</td>
<td>Management of a 60 Year Old Man with a Rising PSA and Normal DRE:</td>
<td>Mark Emberton, MD, FRCS; William C. Huang, MD;</td>
</tr>
<tr>
<td></td>
<td>Panel Discussion</td>
<td>Herbert Lepor, MD; Stacy Loeb, MD, MSc; Peter A.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pinto, MD</td>
</tr>
<tr>
<td>8:30</td>
<td>Energy Sources for Ablating Prostate Cancer</td>
<td>Herbert Lepor, MD</td>
</tr>
<tr>
<td>9:00</td>
<td>Role of Minimally Invasive Ablative Treatment of Prostate Cancer</td>
<td>Herbert Lepor, MD</td>
</tr>
<tr>
<td>9:30</td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>9:45</td>
<td>Risk Stratification of Prostate Cancer: Serum Markers</td>
<td>Stacy Loeb, MD, MSc</td>
</tr>
<tr>
<td>10:05</td>
<td>Risk Stratification of Prostate Cancer: mpMRI</td>
<td>Samir Taneja, MD</td>
</tr>
<tr>
<td>10:25</td>
<td>Risk Stratification of Prostate Cancer: Oncotype</td>
<td>William C. Huang, MD</td>
</tr>
<tr>
<td>10:45</td>
<td>Risk Stratification of Prostate Cancer: Prolaris</td>
<td>Stacy Loeb, MD, MSc</td>
</tr>
<tr>
<td>11:05</td>
<td>Salvage Radical RP vs Salvage Ablation for Recurrent Disease Following Failed Radiation Therapy</td>
<td>William C. Huang, MD</td>
</tr>
<tr>
<td>11:30</td>
<td>Question and Answer</td>
<td></td>
</tr>
<tr>
<td>12:00 pm</td>
<td>Lunch (on your own)</td>
<td></td>
</tr>
<tr>
<td>1:00</td>
<td>In Bore Laser Ablation: Technical Pearls</td>
<td>Daniel Sperling, MD</td>
</tr>
<tr>
<td>1:20</td>
<td>Focal Laser Ablation—Smilow and Sperling Center Experience</td>
<td>Herbert Lepor, MD</td>
</tr>
<tr>
<td>1:50</td>
<td>Cryotherapy: Technical Pearls</td>
<td>Stephen Scionti, MD</td>
</tr>
<tr>
<td>2:10</td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>2:25</td>
<td>Cryotherapy: Clinical Outcomes Focal Ablation</td>
<td>Samir Taneja, MD</td>
</tr>
<tr>
<td>2:50</td>
<td>NYU Experience with RF Focal Ablation</td>
<td>Samir Taneja, MD</td>
</tr>
<tr>
<td>3:05</td>
<td>HIFU: Clinical Outcomes Focal Ablation</td>
<td></td>
</tr>
<tr>
<td>3:45</td>
<td>Moderator: Herbert Lepor, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>What Is the Ideal Energy Source for Tissue Ablation?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Question and Answer/Panel Discussion/Case Presentations</td>
<td></td>
</tr>
<tr>
<td>4:30 pm</td>
<td>Adjourn</td>
<td></td>
</tr>
<tr>
<td>1:20</td>
<td>Focal Laser Ablation—Smilow and Sperling Center Experience</td>
<td>Herbert Lepor, MD</td>
</tr>
<tr>
<td>1:50</td>
<td>Cryotherapy: Technical Pearls</td>
<td>Stephen Scionti, MD</td>
</tr>
<tr>
<td>2:10</td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>2:25</td>
<td>Cryotherapy: Clinical Outcomes Focal Ablation</td>
<td>Samir Taneja, MD</td>
</tr>
<tr>
<td>2:50</td>
<td>NYU Experience with RF Focal Ablation</td>
<td>Samir Taneja, MD</td>
</tr>
<tr>
<td>3:05</td>
<td>HIFU: Clinical Outcomes Focal Ablation</td>
<td></td>
</tr>
<tr>
<td>3:45</td>
<td>Moderator: Herbert Lepor, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>What Is the Ideal Energy Source for Tissue Ablation?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Question and Answer/Panel Discussion/Case Presentations</td>
<td></td>
</tr>
<tr>
<td>4:30 pm</td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>
Registration Form

Advances in Prostate Imaging and Ablative Treatment of Prostate Cancer
Friday–Saturday, June 19-20, 2015
NYU Langone Medical Center, 550 First Avenue (31st Street), Alumni Hall, Farkas Auditorium, New York, NY 10016

PRINT ALL INFORMATION CLEARLY IN BLOCK LETTERS & NUMBERS

Name ___________________________________________________________________________
FIRST M LAST
Address _________________________________________________________________________
City _______________________________________ State __________  Zip _________________

COURSE CONFIRMATION: Please supply your email address to receive a confirmation letter. Make sure your email address is clearly written.

Email ___________________________________________________________________________

Method of Payment:
(Cash, email and phone registration are not accepted)
If faxing, do not mail or refax. This will only result in a duplicate charge to your account. Registration is non-transferable.

☐ Check in U.S. Dollars only: $___________
☐ Credit Card Payment (see below)
☐ International Postal Money Order: $___________
(Foreign registrants, including those from Canada, must pay by International Postal Money Order or credit card.)

PAYMENT BY CREDIT CARD: Credit card payments may be faxed to (212) 263-5293.

Bill To:  ☐ Visa  ☐ MasterCard  ☐ American Express  Amount to be charged: $___________
Credit Card Number: ____________________________ Expiration Date __________ CVV Code __________
Card Member’s Name: ____________________________ Signature ____________________________

REFUND POLICY: In order to request a refund, you must email maria.mercado@nyumc.org no later than 14 days prior to the first day of the course. An administrative fee of $75 will be deducted from your refund. Cancellations or no-shows after this date are not eligible for a refund. Fax and email cancellations are not accepted.

COURSE CANCELLATION POLICY: In the unusual circumstance that this course is cancelled, two weeks notice will be given and tuition will be refunded in full. The NYU Post-Graduate Medical School is not responsible for any airfare, hotel or other costs incurred.

Special needs or requests: ____________________________________________________________
Register online at:
med.nyu.edu/cme/mi

Advances in Prostate Imaging and Ablative Treatment of Prostate Cancer
Friday–Saturday
June 19–20, 2015
New York City